Spots Global Cancer Trial Database for A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
Official Title: A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
Study ID: NCT00719836
Interventions
Study Description
Brief Summary: This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with advanced myeloid malignancies; the second portion of the study is a Phase 2 study to define the efficacy and safety profile of single-agent SB1518 at the recommended dose in subjects with chronic idiopathic myelofibrosis (CIMF).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Chicago Hospitals, Chicago, Illinois, United States
MD Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact Details
Name: Srdan Verstovsek, M.D, Ph.D
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: H. Joachim Deeg, M.D
Affiliation: Fred Hutchinson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Olatoyosi M. Odenike, M.D.
Affiliation: The University of Chicago Hospitals
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
